Cilostazol Attenuates Gray and White Matter Damage in a Rodent Model of Focal Cerebral Ischemia
Authors:
- 1 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (1) , 223-228
Abstract
Background and Purpose— To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo. Methods— Cilostazol (30 or 50 mg/kg) or vehicle was administered by gavage 30 minutes and 4 hours after the induction of cerebral ischemia by permanent occlusion of the left middle cerebral artery (MCA). Animals were euthanized 24 hours after MCA occlusion, and the volume of gray matter damage was evaluated by quantitative histopathology. Axonal damage was determined with amyloid precursor protein immunohistochemistry. Dynamic susceptibility contrast MRI was used to assess regional cerebral blood volume (CBV) and cerebral blood flow (CBF). Results— Treatment with the higher dose of cilostazol (50 mg/kg) significantly reduced the volume of gray matter damage and axonal damage in the cerebral hemisphere by 45.0% ( P P P Conclusions— Treatment with cilostazol significantly reduced the gray and white matter damage associated with permanent focal ischemia. Cilostazol improved CBV and CBF in the peri-infarct area. The major action of cilostazol is to increase perfusion in the ischemic penumbra.Keywords
This publication has 14 references indexed in Scilit:
- The Phosphodiesterase 3 Inhibitor Cilostazol Dilates Large Cerebral Arteries in Humans without Affecting Regional Cerebral Blood FlowJournal of Cerebral Blood Flow & Metabolism, 2004
- Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats—an MRI studyBrain Research, 2003
- New Method for the Quantitative Assessment of Axonal Damage in Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2002
- Toward Wisdom From FailureStroke, 2002
- Effects of Cilostazol, a Selective Cyclic AMP Phosphodiesterase Inhibitor on Isolated Rabbit Spinal Arterioles.The Japanese Journal of Physiology, 2002
- Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarctionJournal of Stroke and Cerebrovascular Diseases, 2000
- Viability thresholds and the penumbra of focal ischemiaAnnals of Neurology, 1994
- Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric arteryEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia.Journal of Neurology, Neurosurgery & Psychiatry, 1987
- Focal Cerebral Ischaemia in the Rat: 1. Description of Technique and Early Neuropathological Consequences following Middle Cerebral Artery OcclusionJournal of Cerebral Blood Flow & Metabolism, 1981